<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 17, 1997
BIOFIELD CORP.
------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-27848 13-3703450
--------------- ---------------- -------------
(State or other (Commission File (IRS Employer
jurisdiction of Number) Identification
incorporation) No.)
1225 Northmeadow Parkway, Suite 120, Roswell, Georgia 30076
-----------------------------------------------------------
(Address of Principal executive offices)
Registrant's Telephone Number, including
area code: (770) 740-8180
Not Applicable
-----------------------------------
(Former Address, if changed since last report)
--------------------------------------------------
<PAGE> 2
Item 5. Other Events
Attached hereto as Exhibit 99.1 is a copy of a press release of
Biofield Corp. (the "Company") announcing that Harvey Horowitz, Esq.
has become a director of the Company following the resignation earlier
this month of director W. Clarke Wescoe, M.D.
Attached hereto as Exhibit 99.2 is a copy of a press release of
the Company announcing the appointment of D. Carl Long as acting
president and chief executive officer of the Company following the
resignation of president and chief executive officer Kenneth W. Anstey.
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(c) Exhibits
99.1 Press Release issued by Biofield Corp. on March 17, 1997.
99.2 Press Release issued by Biofield Corp. on March 17, 1997.
-2-
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOFIELD CORP.
Date: March 20, 1997 By: /s/ Timothy G. Roche
--------------- -------------------------------
Timothy G. Roche
Director of Finance and
Corporate Controller
-3-
<PAGE> 1
Exhibit 99.1
CONTACT: Michael R. Gavenchak Beth Humphreys
Executive Vice President Claudia D'Avanzo
General Counsel Fleishman-Hillard
(770) 740-8180 (404) 659-4446
FOR IMMEDIATE RELEASE
BOEFIELD ANNOUNCES NEW BOARD MEMBER
ATLANTA, GA - March 17, 1997 --Biofield Corp. (NASDAQ:BZET) today
announced that Harvey Horowitz, Esq. has become a director of the company.
Mr. Horowitz is the vice president, general counsel and a director of
Donnkenny, Inc., a publicly traded apparel company. Prior to joining Donnkenny
in October 1996, Mr. Horowitz had been the managing partner of the New York
based law firm Squadron, Ellenoff, Plesent & Sheinfeld LLP, which is the
company's outside law firm. The addition of Mr. Horowitz to the company's
board of directors follows the resignation earlier this month of director W.
Clarke Wescoe, M.D. Dr. Wescoe, who cited personal reasons for his
resignation, is the retired chairman of the board and chief executive officer
of Sterling Drug, Inc. He served on the company's board of directors from
August 1992.
Biofield Corp, is a medical technology company that has developed an
innovative system for detecting breast cancer through the skin in a
non-invasive and objective procedure. The company is based in Atlanta.
###
-end-
<PAGE> 1
Exhibit 99.2
CONTACT: Michael R. Gavenchak Tony DeMartino
Executive Vice President Claudia D'Avanzo
General Counsel Fleishman-Hillard
(770) 740-8180 (404) 659-4446
FOR IMMEDIATE RELEASE
D. CARL LONG APPOINTED ACTING PRESIDENT AND CHIEF EXECUTIVE OFFICER OF BIOFIELD
ATLANTA, GA - March 17, 1997 --Biofield Corp. (NASDAQ:BZET) today
announced that D. Carl Long, its vice chairman, director, and former chief
executive officer, has been appointed acting president and chief executive
officer of the company. Mr. Long will replace Kenneth W. Anstey who resigned
today as president and chief executive officer. Mr. Anstey stated that his
resignation followed differences with the company over its management structure
and does not reflect any loss of confidence in the company's technology or
breast cancer detection system. Mr. Long served as chief executive officer of
Biofield from September 1992 until Mr. Anstey joined the company in December
1995.
Biofield Corp. is a medical technology company that has developed an
innovative system for detecting breast cancer through the skin in a
non-invasive and objective procedure. The company is based in Atlanta.
###
-end-
